Z-COVID-19 Funding Opportunities

COVID-19 Research Grants for Combating the coronavirus crisis

Various government agencies, companies, and foundations have announced non-dilutive funding opportunities to encourage research and development to address the novel Coronavirus pandemic. Some of these opportunities allow applicants to propose new projects addressing COVID-19, while others provide funding to expand the scope of existing awards to include COVID-19-related research.

As the COVID-19 situation continues to develop, EGC will maintain an updated list of relevant funding opportunities here. Click below to be notified as new COVID-19 research grants are announced.


Expand/Collapse All


Biomedical Advanced Research and Development Authority (BARDA)

BARDA continues to solicit proposals for the development of diagnostic assays and therapeutics for COVID-19 and encourages applicants to participate in a TechWatch meeting prior to submitting a white paper or full proposal in response to its current Broad Agency Announcement

BARDA Broad Agency Announcement (BAA)

View Solicitation


BARDA is currently seeking applications for funding of therapeutic monoclonal antibody development for treating COVID-19 and of next-generation COVID-19 vaccine development.

Topics: Through Topic 9.9 “COVID-19 Monoclonal Antibody Therapeutics for Treatment,” BARDA is interested in supporting the manufacturing, FDA Emergency Use Authorization (EUA) and regulatory licensure of new monoclonal antibodies (mAbs) effective at treating SARS-CoV-2 infection, particularly in special populations, such as adults and pediatrics who may be moderately to severely immune compromised.

Through Area of Interest #15 “Next-generation COVID-19 Vaccines,” BARDA is taking a targeted approach to de-risk key vaccine development efforts to have as broad an impact as possible across the vaccine development space, rather than focusing on funding entire development plans for just a small subset of vaccines. The largest effort will focus on generating proof-of-concept Phase IIb efficacy data. Amongst other requirements, the program must have an active or complete Phase 1 clinical trial, with unblinded safety and immunogenicity data to support a Phase IIb trial available no later than 6 months after proposal submission

Due Date: 9/25/2023
Budget: Not specified



View Solicitation

Description: BARDA’s s EZ-BAA aims to accelerate innovations and improve the availability of transformative products and technologies to protect Americans from natural and intentional health security threats. DRIVe is seeking transformative and innovative approaches that are outside of the mainstream, challenge assumptions, require multi-disciplinary teaming, and have the potential to radically change established practices, lead to extraordinary outcomes, and create entirely new fields. DRIVe is interested in projects that span the entire product development spectrum (but this may vary within each Area of Interest [AOI]).


  • AOI #18 Host-Directed Therapeutics — BARDA is interested in advancing host-directed therapies aimed at fortifying and restoring balance to the body’s defense mechanisms. This class of therapeutics is pathogen agnostic, and applications related to the response to SARS-CoV-2 infection may be submitted. The topic focuses on four areas: i) patient stratification or endotyping approaches; ii) mitigating long-term effects of infectious disease ; iii) preventing or mitigating severe outcomes of infectious disease; and iv) repurposing pulmonary disease therapies for pandemic preparedness.
  • AOI #19 Healing Lungs – DRIVe is interested in developing novel technologies to sustain healthy oxygenation levels in ARDS patients as they heal naturally or await lung transplant and to prevent further tissue injury to already damaged lungs. The Division is also interested in advancing solutions for patients who are refractory to mechanical ventilation. DRIVe is seeking two types of novel technological solutions for severe ARDS patients: 1) non-ECMO methods of oxygen delivery (e.g., synthetic and mammalian-cell-derived oxygen carriers) that may offer alternative options to severe ARDS management and 2) innovations that simplify the implementation and operation of VV-ECMO, improve its safety profile, and potentially enhance its availability outside of specialized ECMO centers.
  • AOI #20 DRIVe Forward – Submissions under this AOI are designed to address blindspots in preparedness for emerging infectious diseases, pandemics, and other public health emergencies either as a standalone proof of concepts or as a prelude to a potential future program. Topics of interest that are relevant to COVID-19/SARS-CoV-2 include microbiome-based therapies; resilience to infection; next-generation vaccines; next-generation therapeutic antibodies; extremely mobile viral diagnostic platforms for use in extremely remote settings; and non-pharmacological approaches for enhanced immunity.
  • AOI #21, Vaccines on Demand – BARDA seeks to advance the development of On Demand Vaccine Manufacturing technologies/systems for distributed vaccine production at or near the point of service, with a particular focus on nucleic-acid-based vaccines.
  • AOI #23, Host-based Diagnostics – BARDA is interested in advancing the development of host-based diagnostics in three focal areas: i) determination of immunological status post-infection; ii) improving patient-centric care outside the hospital or post-discharge; and iii) demonstrating clinical utility.

Due Dates: Vary by Area of Interest
Budget: The total Government-funded share of the project budget should be less than $750,000

TechWatch Meetings

Request a Meeting

Description: Through TechWatch meetings, the U.S. Government seeks information from stakeholders on available medical countermeasures in development, especially products, technologies, and capabilities that have progressed into or beyond clinical trials, have established large-scale cGMP manufacturing capability, or utilize an approved platform. Information regarding diagnostics, therapeutics, vaccines, and other products, technologies, or capabilities that are relevant to responses to public health emergencies (including COVID-19) is sought.

National Institutes of Health (NIH)
Notices of Special Interest (NOSI)

Administrative Supplements for Research of Emerging and Existing Issues of COVID-19 Related to the Health and Well-Being of Women, Children and Individuals with Physical and/or Intellectual Disabilities

Description: This Administrative Supplement provides an opportunity for funded researchers in various fields to pursue supplemental funding to conduct research addressing emerging and other existing COVID-related issues among pregnant and lactating people, infants, children and adolescents, and individuals with physical and/or intellectual disabilities. Its purpose is to complement existing COVID-related funding opportunities by supporting currently funded investigators in addressing key issues not covered by the available COVID-related funding announcements among these populations. Applications should fall within the mission of at least one of the following Institutes: the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute on Drug Abuse (NIDA), and the National Institute of Neurological Disorders and Stroke (NINDS).

Topics: Areas of interest include menstrual health, fertility, pregnancy, and perinatal issues; vaccination studies; pharmacology issues; developmental and schooling impacts; testing studies for COVID and related conditions; mental health concerns; viral strains and other viral issues; viral co-infections; pandemic effects; and neurological effects.

Due Date: May vary by awarding Institute/Center (IC). Please refer to the IC’s website for details.
Budget: Up to $100,000 in direct costs for NINDS; for other ICs, the total requested budget may not exceed the amount of the parent award.

National Eye Institute

Notice of Special Interest (NOSI): Addressing Accessibility Inequities with COVID Home-Based Testing for Individuals with Visual Impairment

Description: The National Eye Institute has issued a Notice of Special Interest to encourage the development and implementation of specific, targeted approaches for home-based COVID-19 testing that is accessible for people with visual impairment. Strategies should be scalable, sustainable, and consider the multiple stakeholders (e.g., visually impaired, blind children, adults with low vision, older adults, parents/guardians, caregivers).

Topics: Key issues to be addressed include but are not limited to:

  • Determining appropriate testing approaches (surveillance, screening, and/or diagnostic testing) for people who are visually impaired 
  • Reducing barriers to home -testing and establishing testing strategies suitable for people who are visually impaired
  • Developing new technologies to address current limitations

Due Date: Varies by funding opportunity
Budget: Varies by funding opportunity

National Institute of Mental Health (NIMR)
Notice of Special Interest (NOSI): COVID-19 Pandemic Mental Health Research

Description: The NIMH has issued a Notice of Special Interest in basic, translational, interventional, and services research relevant to the COVID-19 pandemic. A key area of interest is the development of scalable interventions to meet the public mental health needs during and resulting from the pandemic, including not only those needs that are specifically related to the virus but also the needs of the broader population that is impacted by stress, disruptions, and loss of lives in the pandemic. Applicants may submit proposals to the R01, R21, and R34 programs.

Topics: Relevant topics of interest include the following:

  • Projects to develop and test tools that would enable health and social service workers to have real-time access to resources for case management and referral to medical/psychiatric treatment, as well as social support services, to meet the complex needs of persons with mental illness.
  • Research to determine the feasibility and utility of technology-enabled screening to identify/triage those in immediate need of in-patient behavioral health, medications, and opioid replacement therapy. Higher priority research would include evaluation of participant follow through and outcomes related to point-of-care triage and referral to services (e.g., web-based or other self-care, and/or telephone counseling that supports individual brief cognitive behavioral therapy (CBT) for distress, online group interventions, etc.).
  • Development and testing of technology to leverage/build on the available response workforce to enable practical, scalable, and sustainable mental health screening, triage, and prevention/treatment interventions along a continuum of intensity for mental disorders across the lifespan, particularly for high-risk populations both within and outside healthcare settings (i.e., school or workplace screening is also of interest). Interventions appropriate for mass trauma response are of interest (e.g., Psychological First Aid [PFA]; enhanced PFA; self-guided and professionally assisted skills-based interventions, internet-based interventions for managing common posttraumatic symptoms and stress related symptoms and conditions; brief CBT-based approaches for distress, and Collaborative Care programs) as are those to improve de-escalation of suicidal crises, reduce suicide attempt risk, and/or improve post-acute recovery for youth at elevated risk for self-injurious thoughts and behaviors treated in acute care settings).

Due Date: Varies by program
Budget: Varies by program




<! –– This is javascript that makes the expand/collapse button work ––>